In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ProQinase GMBH

Executive Summary

ProQinase GMBH was established as a wholly owned subsidiary of the Tumor Biology Centre (TBC), Freiburg, in April 2001 to commercialize the centre's research on protein kinases. During their years of basic research at TBC, ProQinase's scientists have developed extensive know-how in the protein kinase arena and have established a range of tools and assays to identify, produce, manipulate and screen protein kinases' activities. These tools and assays now constitute the Integrated Technology Platform Protein Kinases that ProQinase is commercializing through a hybrid business model. The company will apply the platform technology to its own in-house drug discovery and development activities and also make it available to external clients on a fee-for-service basis.

You may also be interested in...



Working Around Pre-Emption Rights

Europe's pre-emption rights significantly hamper biotech fundraising. But since they're unlikely to go away, European firms are having to find clever ways around them.

Lectus Therapeutics Ltd.

Lectus was founded in December 2002, to develop and commercialize a second generation of ion channel modulating drugs. By targeting the plethora of accessory proteins that regulate the activity of the ion channel pore-forming proteins rather than the pore-forming proteins themselves Lectus believes its drugs will be safer and more effective than currently marketed products.

Senexis Ltd.

Senexis Ltd. spun-out of the University of Manchester Institute of Science and Technology to develop novel therapeutics and diagnostics for currently incurable aging-related disorders such as Alzheimer's disease, Parkinson's disease and type 2 diabetes. In addition to being more prevalent in the older population, these diseases also share a similar underlying etiology; they are all associated with amyloidosis.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC031354

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel